EUVIMEDEUVIMED entdecken
Crossref

Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study

Simon Fletcher iD, Kathryn Jenner, Michael Holland, Kate Khair iD

Haemophilia · 2023

DOI: 10.1111/hae.14774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2023. Verfasst von Simon Fletcher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Hauptthemen laut MEDLINE: Hemophilia A, Hemophilia B. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: The Exigency study programme is funded by an unrestricted educational grant by uniQure Biopharma B.V. to Haemnet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Qualitative studies have explored why people with haemophilia (PwH) might consider or forgo gene therapy, the impact it has had on those who have received it, and what support might be needed throughout the process. No studies have yet examined what withdrawal prior to transfection might mean for PwH and their families.

Aims

To understand the experiences of PwH and their families of withdrawal from gene therapy and to understand what support mechanisms might be required.

Methods

Qualitative interviews were conducted with people with severe haemophilia who consented to take part in a gene therapy study in the UK but either withdrew or were withdrawn before transfection.

Results

Nine PwH and a family member were invited to this sub‐study. Eight participants were recruited: six PwH (five haemophilia A and one haemophilia B) and two family members. Four participants were excluded from a study after consenting but before transfection, having failed to meet all the inclusion criteria; two withdrew after consenting but before transfection due to concerns including duration of factor expression and the time commitment involved in follow‐up. The mean age of participants was 40.5 years (range 25–63 years). Two major themes emerged during the interviews: Expectation and loss.

Conclusions

PwH have many expectations about the difference gene therapy can make to their lives. Studies show that these expectations may not be fully realised. For those who have either withdrawn or been withdrawn from gene therapy, any expectations they had may now be unachievable. The nature of these expectations and the loss expressed by the participants indicate that support needs to be provided to help them and their families manage it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemophilia BHumansAdultMiddle AgedMotivationFamilyPhysical Therapy Modalities

Stichwörter der Autor:innen

clinical trialsdecision makinggene therapygrief and losshaemophilia

Autor:innen und Institutionen

  • Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Haemnet, London, UK.

ORCID-Profile: Simon Fletcher, Kate Khair

Förderung

  • The Exigency study programme is funded by an unrestricted educational grant by uniQure Biopharma B.V. to Haemnet

Zitieren

APA

Fletcher, S., Jenner, K., Holland, M., & Khair, K. (2023). Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study. Haemophilia. https://doi.org/10.1111/hae.14774

Vancouver

Fletcher S, Jenner K, Holland M, Khair K. Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study. Haemophilia. 2023. doi:10.1111/hae.14774

BibTeX
@article{Fletcher2023,
  author = {Fletcher, Simon and Jenner, Kathryn and Holland, Michael and Khair, Kate},
  title = {Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study},
  journal = {Haemophilia},
  year = {2023},
  doi = {10.1111/hae.14774}
}
Kostenlos starten →